1.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CR003583, ET743SAR3002, NCT00210665
|
|
2.
|
Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: Under 50 Sponsor: NCI, Other Protocol IDs: CDR0000487560, COG-ARST0531, ARST0531, NCT00354835
|
|
3.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: E7389-G000-309, NCT01327885
|
|
4.
|
Phase: Phase III Type: Treatment Status: Active Age: 15 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CR018004, ET743SAR3007, NCT01343277
|
|
5.
|
Phase: Phase III Type: Treatment Status: Active Age: 15 and over Sponsor: Pharmaceutical / Industry Protocol IDs: TH-CR-406/SARC021, NCT01440088
|
|
6.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000628781, UCDCC-216, BAYER-UCDCC-216, NCT00805727
|
|
7.
|
Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2011-01412, 10-049, CDR0000680558, MSKCC-10049, U01CA069856, 8406, NCT01154452
|
|
8.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 11-104, NCT01418001
|
|
9.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: 12-100, NCT01659203
|
|
10.
|
Phase: Phase II Type: Treatment Status: Active Age: 25 and under Sponsor: Other Protocol IDs: RTSARC, NCT00186992
|
|
11.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: 05-090, 1 R21 CA117128-01A1, NCT00356031
|
|
12.
|
Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: Any age Sponsor: Other Protocol IDs: 05-122, MSKCC-05122, NCT00445965
|
|
13.
|
Phase: Phase II Type: Treatment Status: Active Age: 30 and under Sponsor: NCI, Other Protocol IDs: 05-326, Other, NCT00592293
|
|
14.
|
Phase: Phase II Type: Treatment Status: Active Age: 21 and under Sponsor: NCI, Other Protocol IDs: 04-188, P01CA021239, NCT00592592
|
|
15.
|
Phase: Phase II Type: Treatment Status: Active Age: 13 and over Sponsor: Other Protocol IDs: SARCOMA0006, SU-01202010-4743, 17755, NCT01055028
|
|
16.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 10-094, NCT01209598
|
|
17.
|
Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: HCI45197, NCT01259375
|
|
18.
|
Phase: Phase II Type: Treatment Status: Active Age: 3 to 55 Sponsor: Other Protocol IDs: 2009-0528, NCT01277744
|
|
19.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: MCC-16441, NCT01347034
|
|
20.
|
Phase: Phase II Type: Treatment Status: Active Age: 15 to 80 Sponsor: Pharmaceutical / Industry Protocol IDs: INNO-206-P2-STS-01, NCT01514188
|
|
21.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: UPCC 09510, NCT01561495
|
|
22.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 to 90 Sponsor: Other Protocol IDs: MUSC 101644, PAZ115785, NCT01593748
|
|
23.
|
Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2012-01978, A091103, CDR0000735380, CALGB-A091103, U10CA031946, NCT01623869
|
|
24.
|
Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2012-01991, A091102, CDR0000737403, CALGB-A091102, U10CA031946, NCT01653028
|
|
25.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: SARC016, NCT01661283
|